Outlook Therapeutics Inc.

08/07/2024 | Press release | Distributed by Public on 08/07/2024 11:46

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.